Interpace Diagnostics Joins the Fight Against Pancreatic Cancer at the Pittsburgh PurpleStride Event Jul 13, 2017
Interpace Diagnostics Announces Pricing of $13.7 Million Underwritten Public Offering of Common Stock and Common Warrants Jun 16, 2017
Interpace Diagnostics Group Reports First Quarter 2017 Financial Results, Business Progress and Recent Accomplishments May 15, 2017
Interpace Diagnostics to Host Conference Call and Webcast to Discuss First Quarter 2017 Financial Results on Monday May 15, 2017 May 12, 2017
